We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+29.16%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$2.01B
AUM Growth
+$536M
Cap. Flow
+$287M
Cap. Flow %
14.23%
Top 10 Hldgs %
41.55%
Holding
100
New
24
Increased
34
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$52.5M
2
MDT icon
Medtronic
MDT
+$51M
3
ISRG icon
Intuitive Surgical
ISRG
+$45.3M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$37.4M
5
DXCM icon
DexCom
DXCM
+$32.3M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$63.9M
2
THC icon
Tenet Healthcare
THC
+$40.4M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$30.1M
4
BTSG icon
BrightSpring Health Services
BTSG
+$13.4M
5
PFE icon
Pfizer
PFE
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
51
DELISTED
Arcellx
ACLX
$13M 0.65%
200,000
+50,000
+33% +$3.99M
DGX icon
52
Quest Diagnostics
DGX
$26.2B
$13M 0.65%
75,000
-10,000
-12% -$1.82M
SANA icon
53
Sana Biotechnology
SANA
$1.05B
$12.2M 0.61%
3,000,000
+1,000,000
+50% +$4.48M
TARA icon
54
Protara Therapeutics
TARA
$220M
$12M 0.6%
2,250,000
+850,000
+61% +$4.73M
PRAX icon
55
Praxis Precision Medicines
PRAX
$10.3B
$11.8M 0.59%
+40,000
New +$7.45M
DNTH icon
56
Dianthus Therapeutics
DNTH
$6.07B
$11.3M 0.56%
275,000
+125,000
+83% +$4.85M
NVST icon
57
Envista
NVST
$4.58B
$10.9M 0.54%
500,000
-50,000
-9% -$1.03M
EHC icon
58
Encompass Health
EHC
$12.4B
$10.6M 0.53%
100,000
-100,000
-50% -$11.6M
ORIC icon
59
Oric Pharmaceuticals
ORIC
$1.42B
$9.82M 0.49%
1,200,000
+300,000
+33% +$3.45M
MLYS icon
60
CALL
Mineralys Therapeutics
MLYS
$2.41B
$9.07M 0.45%
+250,000
New +$10M
CRL icon
61
Charles River Laboratories
CRL
$13.5B
$8.98M 0.45%
45,000
-15,000
-25% -$2.72M
CELC icon
62
Celcuity
CELC
$4.3B
$7.98M 0.4%
+80,000
New +$6.58M
INSP icon
63
Inspire Medical Systems
INSP
$1.71B
$6.92M 0.34%
75,000
-45,000
-38% -$4.31M
ANRO icon
64
Alto Neuroscience
ANRO
$1.12B
$6.67M 0.33%
375,000
-25,000
-6% -$315K
LNTH icon
65
Lantheus
LNTH
$6.57B
$6.66M 0.33%
+100,000
New +$5.82M
ARWR icon
66
Arrowhead Research
ARWR
$12.6B
$6.64M 0.33%
100,000
-125,000
-56% -$6.13M
BRKR icon
67
Bruker
BRKR
$8.69B
$5.89M 0.29%
+125,000
New +$5.28M
NRIX icon
68
Nurix Therapeutics
NRIX
$2.69B
$5.69M 0.28%
300,000
-50,000
-14% -$718K
ELAN icon
69
Elanco Animal Health
ELAN
$11.4B
$5.66M 0.28%
250,000
-550,000
-69% -$12M
APLS
70
DELISTED
Apellis Pharmaceuticals
APLS
$5.02M 0.25%
200,000
-50,000
-20% -$1.17M
RZLT icon
71
Rezolute
RZLT
$445M
$4.72M 0.23%
2,000,000
– –
DFTX
72
Definium Therapeutics
DFTX
$5.43B
$4.69M 0.23%
+350,000
New +$4.33M
SNDX icon
73
Syndax Pharmaceuticals
SNDX
$1.81B
$4.2M 0.21%
+200,000
New +$3.49M
MAZE
74
Maze Therapeutics
MAZE
$1.51B
$4.14M 0.21%
+100,000
New +$3.44M
EYPT icon
75
EyePoint Inc
EYPT
$1.13B
$3.65M 0.18%
+200,000
New +$2.83M
1 2
3
4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Integral Health Asset Management held 100 positions worth $2.01B, up 36% from $1.48B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Integral Health Asset Management deployed $287M of net new capital in Q4 2025, opening 24 new positions and adding to 34 existing holdings. Its largest new stake was DexCom: 500,000 shares worth $33.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $63.9M trimmed.

  • Integral Health Asset Management's largest Q4 2025 buy was DexCom: 500,000 shares worth $33.2M.
  • Integral Health Asset Management added most to Revolution Medicines in Q4 2025, an estimated $52.5M increase.
  • Integral Health Asset Management's biggest Q4 2025 reduction was Insmed, cutting an estimated $63.9M.
  • Integral Health Asset Management fully exited Pfizer in Q4 2025, selling an estimated $12.7M.
  • Integral Health Asset Management's ten largest holdings make up 42% of its $2.01B portfolio in Q4 2025.
  • Integral Health Asset Management opened 24 new positions and closed 14 in Q4 2025.
  • Integral Health Asset Management's portfolio value rose 36% quarter-over-quarter to $2.01B.

Based on Integral Health Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.